Maintaining Patient QoL through Optimal Management of ADC-Associated AEs
Patients with HER2-negative metastatic breast cancer (MBC) who receive antibody-drug conjugates (ADCs) may experience a spectrum of adverse events (AEs) that can lower their quality of life (QoL). Patients and caregivers rely on their care team…